Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

N Engl J Med. 2023 Aug 3;389(5):477. doi: 10.1056/NEJMc2306786.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / pathology
  • Humans
  • Ipilimumab / adverse effects
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / pathology
  • Nivolumab

Substances

  • Nivolumab
  • Ipilimumab
  • cabozantinib